[Leish-l] antagonists tnf-alpha and kala-azar

[Michal Baniyash]

Dear Dr. Carlos,

Thanks for your e-mail.

Based on our preliminary data using mouse models for inducible cancer, etanercept treatment works and we get lower tumor burden and improved immune status. We have also some preliminary data on leishmaniasis in mice, pointing at elevated levels of MDSCs and an immunosuppressive immune status but we did not yet try the etanerecpt treatments. Based on the studies in the literature anti-TmTNF antibodies affect better TmTNF+ cells with intracellular pathogens, while  etanercept is better in neutralising soluble TNF. These anti-TNF reagents all help but at different pathways; etanercept will neutralise efficiently soluble TNF, which we know today is a key modifier of MDSCs and thus, could have a positive impact to immune functions recovery, while anti-TNF antibodies is more effective in acting via the TmTNF that could directly affect infected cells. We can further discuss these issues.

Regards

Michal
------------------------------
Prof. Michal Baniyash, Ph.D
The Lautenberg Center for General and Tumor Immunology
IMRIC, Hebrew University, Hadassah Medical School
POB 12272, Jerusalem 91120, Israel
Tel: 972-2-6757461
Fax: 972-2-6424653
E-mail: baniyash at cc.huji.ac.il<mailto:baniyash at cc.huji.ac.il>






On Nov 30, 2013, at 11:52 PM, josé carlos <jcribeiro.pi at ig.com.br<mailto:jcribeiro.pi at ig.com.br>>
 wrote:

Dear friends,

I thought better and think etanercept or will not be useful in chronic infections such as leishmaniasis and even in cancers. etanercept acts on soluble TNF-alpha that is precisely what is elevated in autoimmune diseases. In cases of infections and cancer predominates transmembrane TNF-alpha which is the target of anti-TNF alpha monoclonal antibodies. So, in my humble opinion I believe that the research of leishmaniasis should be investigated antagonists monoclonal antibody type and non-receptor soluble. What do you think?

Regards,

José Carlos


On Nov 29, 2013, at 1:09 PM, josé carlos <jcribeiro.pi at ig.com.br<mailto:jcribeiro.pi at ig.com.br>> wrote:

Good Morning Dr. baniyash,

I am a Brazilian doctor who study leishmaniasis, an infectious disease characterized by chronic inflammation and immunosuppression. I read your article Tumor Necrosis Factor-a Blocks Differentiation and Enhances Suppressive Activity of ImmatureMyeloid Cells during Chronic Inflammationand thought that kala azar in the MDSC are elevated use of etanercept at the appropriate time could represent a cure for these patients.

regards,

josé carlos

-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lineu.icb.usp.br/pipermail/leish-l/attachments/20131201/789c186d/attachment.htm>